

IN THE CLAIMS:


Please cancel claims 8, 9, 18, 19, 27 and 33 without prejudice.

Please amend claims 1, 11, 12 and 30 as indicated below.

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of the general formula I



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R1 is a saturated ~~or unsaturated~~, substituted ~~or unsubstituted~~ hydrocarbon chain having from 2 to 30 carbon atoms;

R2 is ~~H or~~ a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;

D is ~~the residue of a nonsteroidal anti-inflammatory drug having a functional group selected from the group consisting of carboxyl, hydroxyl, amine and thiol indomethacin~~, wherein D is attached through ~~said~~ a functional group to a bridging group, -C(O)-Z-X-, wherein Z is a

saturated ~~or unsaturated~~ hydrocarbon chain having from 2 to 15 carbon atoms, and X is selected from amino, ~~hydroxy, and thio and carbonyl groups, such that when the functional group of D is carboxyl, X is selected from amino, hydroxy and thio, and when the functional group of D is~~ amino, hydroxy or thio, X is a carbonyl group.

2. (Previously Amended) The compound according to claim 1, wherein the conjugated residue of the nonsteroidal ant-inflammatory drug is pharmacologically inactive.
3. (Original) The compound according to claim 1, wherein an ester bond at position sn-2 of the phospholipid of the general formula I is cleaveable by a lipase.
4. (Original) The compound according to claim 3, wherein said lipase is a phospholipase.
5. (Original) The compound according to claim 4, wherein said phospholipase is phospholipase A₂ (PLA₂).
6. (Original) The compound according to claim 1, wherein R1 is an hydrocarbon chain having from 10 to 20 carbon atoms.
7. (Original) The compound according to claim 1, wherein R1 is an hydrocarbon chain having 15 or 17 carbon atoms.
8. (Canceled)
9. (Canceled)
10. (Previously Amended) The compound according to claim 1 selected from the group consisting of:
1-Stearoyl-2-{3-[2-(2,6-dichloroanilino)phenylacetamido]propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{4-[2-(2,6-dichloroanilino)phenylacetamido]butanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{5-[2-(2,6-dichloroanilino)phenylacetamido]valeroyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[2-(2,6-dichloroanilino)phenylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{8-[2-(2,6-dichloroanilino)phenylacetamido]octanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{12-[2-(2,6-dichloroanilino)phenylacetamido]dodecanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{3-[α -methyl-4-(2-methylpropyl)benzeneacetamido] propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[α -methyl-4-(2-methylpropyl)benzeneacetamido] hexanoyl}-sn-glycero-3-phosphocholine,


1-Stearoyl-2-{3-[(S)-6-methoxy- α -methyl-2-naphtaleneacetamido] propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{4-[(S)-6-methoxy- α -methyl-2-naphtaleneacetamido] butanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[(S)-6-methoxy- α -methyl-2-naphtaleneacetamido] hexanoyl}-sn-glycero-3-phosphocholine, and

1-Stearoyl-2-{4-[2-(6-methoxynaphthyl)acetamido]butanoyl}-sn-glycero-3-phosphocholine.

11. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound of the general formula I



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R1 is a saturated ~~or unsaturated~~, substituted ~~or unsubstituted~~ hydrocarbon chain having from 2 to 30 carbon atoms;

R2 is ~~H~~ or a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;

D is ~~the residue of a nonsteroidal anti-inflammatory drug having a functional group selected from the group consisting of carboxyl, hydroxyl, amine and thiol~~ indomethacin, wherein D is attached through ~~said a~~ functional group to a bridging group, -C(O)-Z-X-, wherein Z is a saturated ~~or unsaturated~~ hydrocarbon chain having from 3 to 15 carbon atoms, and X is selected from amino, ~~hydroxy, and thio and carbonyl groups, such that when the functional group of D is carboxyl, X is selected from amino, hydroxy and thio, and when the functional group of D is amino, hydroxy or thio, X is a carbonyl group.~~

12. (Currently Amended) The pharmaceutical composition according to claim 11, wherein -C(O)-Z-X-D is an inactive ~~drug~~ derivative of D.

13. (Original) The pharmaceutical composition according to claim 11, wherein an ester bond at position sn-2 of the phospholipid of the general formula I is cleaveable by a lipase.

14. (Original) The pharmaceutical composition according to claim 13, wherein said lipase is a phospholipase.

15. (Original) The pharmaceutical composition according to claim 14, wherein said phospholipase is phospholipase A₂ (PLA₂).

16. (Original) The pharmaceutical composition according to claim 11, wherein R1 is an hydrocarbon chain having from 10 to 20 carbon atoms.

17. (Original) The pharmaceutical composition according to claim 11, wherein R1 is an hydrocarbon chain having 15 or 17 carbon atoms.

18. (Canceled)

19. (Canceled)

20. (Previously Amended) The pharmaceutical composition according to claim 11, wherein said compound of the general formula I is selected from the group consisting of:

1-Stearoyl-2-{3-[2-(2,6-dichloroanilino)phenylacetamido]propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{4-[2-(2,6-dichloroanilino)phenylacetamido]butanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{5-[2-(2,6-dichloroanilino)phenylacetamido]valeroyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[2-(2,6-dichloroanilino)phenylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{8-[2-(2,6-dichloroanilino)phenylacetamido]octanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{12-[2-(2,6-dichloroanilino)phenylacetamido]dodecanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{3-[α -methyl-4-(2-methylpropyl) benzeneacetamido]propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[α -methyl-4-(2-methylpropyl)benzeneacetamido] hexanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{3-[(S)-6-methoxy- α -methyl-2-naphtaleneacetamido]propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{4-[(S)-6-methoxy- α -methyl-2-naphtaleneacetamido] butanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[(S)-6-methoxy- α -methyl-2-naphtaleneacetamido] hexanoyl}-sn-glycero-3-phosphocholine, and

1-Stearoyl-2-{4-[2-(6-methoxynaphtyl)acetamido]butanoyl}-sn-glycero-3-phosphocholine.

21. (Previously Amended) The pharmaceutical composition according to claim 11, in the form of solutions, suspensions, capsules, tablets, aerosols, gels, ointments or suppositories.

22. (Previously Amended) The pharmaceutical composition according to claim 11 for oral, ocular, nasal, parenteral, topical or rectal administration.

23. (Original) The pharmaceutical composition according to claim 22 for oral administration.

24. (Original) The pharmaceutical composition according to claim 22 for nasal administration.

25. (Previously Amended) The pharmaceutical composition according to claim 11 for the treatment of a disease or disorder related to an inflammatory condition.

26. (Original) The pharmaceutical composition according to claim 25, wherein said disease or disorder related to an inflammatory condition is selected from the group consisting of arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.

27. (Canceled)

28. (Previously Amended) A method for treatment of a disease or disorder related to an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 11.

29. (Original) The method according to claim 28, wherein said disease or disorder related to an inflammatory condition is selected from the group consisting of arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.

30. (Currently Amended) A process for the synthesis of compounds of the general formula I as defined in claim 1, comprising:

-
- (i) providing a molecule $y\text{-X-Z-COOH}$, wherein y is selected from H and OH, Z is a saturated ~~or unsaturated~~ hydrocarbon chain having from 2 to 15 carbon atoms, and X is selected from amino, ~~hydroxy~~, and thio and carbonyl groups;
 - (ii) replacing y with an appropriate blocking group, B, selected from the group consisting of benzyl chloromate, benzyloxycarbonate, diphenylcarbinol and trimethylacetamidocarbinol;
 - (iii) preparing an anhydride of the molecule $B\text{-X-Z-COOH}$ by employing a reagent to remove one molecule of water from two protected bridging groups;
 - (iv) acylating a lyso-lecithin by the anhydride of step (iii) to yield 1-acyl-2-acyl(X-B)-sn-glycero-3 phospholipid by dissolving said anhydride and said lyso-lecithin in an organic solvent in the presence of a catalyst;
 - (v) removing the blocking group B from the functional group X; and
 - (vi) coupling a nonsteroidal anti-inflammatory drug D comprising indomethacin to the functional group X in an organic solvent in the presence of reagents that enable a condensation reaction wherein water molecules are removed, thus, generating a molecule of the general Formula I.

31. (Original) The process according to claim 30 wherein the protected functional group X is -NH.

32. (Original) The process according to claim 30 wherein the phospholipid of step (iv) is phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol or phosphatidylserine.

33. (Canceled)